NCT05869903: An ongoing trial by Eli Lilly and Company
This trial is ongoing. It must report results 7 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05869903 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 5, 2023 |
| Completion date | July 25, 2025 |
| Required reporting date | July 25, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |